GlassScriptPhysician profile
Markham L Nightengale
NPI 1144215971
$1,488.49
in general payments reported to CMS, 2019-2025
19 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $111 · 2021: $263 · 2022: $168 · 2023: $205 · 2024: $199 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $643.68 | 2019-2025 | |
| Olympus America INC. | $188.34 | 2019-2021 | |
| Boston Scientific Corporation | $117.29 | 2019 | |
| Janssen Biotech, INC. | $104.02 | 2021-2023 | Simponi Aria, Remicade, Stelara |
| Pfizer INC. | $82.07 | 2025 | |
| Lilly USA, LLC | $78.92 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $43.60 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.00 | 2022-2023 | Trulance |
| Daiichi Sankyo INC. | $31.20 | 2021-2023 | Injectafer |
| Ucb, INC. | $26.63 | 2019 | |
| Medtronic, INC. | $23.76 | 2025 | Interstim |
| Takeda Pharmaceuticals U.S.A., INC. | $22.79 | 2021 | |
| Nestle Healthcare Nutrition INC. | $20.59 | 2021 | |
| Gilead Sciences, INC. | $18.01 | 2021 | |
| Redhill Biopharma INC. | $16.24 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $13.84 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.78 | 2022 | |
| Qol Medical, LLC | $12.73 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,097.44 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Markham Nightengale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.